Abstract
Prolonged Rapamycin treatment led to beneficial metabolic switch
Highlights
The evolutionarily conserved TOR (Target of Rapamycin) signaling controls growth and metabolism from yeast to mammals [1]
Rapamycin treatment showed the detrimental metabolic effects, including hyperinsulinemia, hyperlipidemia, glucose intolerance and insulin resistance. Those observations present a paradox of improved survival despite metabolic impairments
In the various studies of rapamycin treatment, length of rapamycin treatment varied from two weeks to two years
Summary
The evolutionarily conserved TOR (Target of Rapamycin) signaling controls growth and metabolism from yeast to mammals [1]. Mammalian or mechanistic TOR (mTOR) plays the key role in aging and agerelated disease [2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
